Revenue rises to 7.8m pounds in full year at Oxford Biomedica
Gene-based biopharmaceutical company Oxford BioMedica has reported that revenue rose to 7.8m pounds in the full year 2012 from 7.7m pounds one year earlier.
Gene-based biopharmaceutical company Oxford BioMedica has reported that revenue rose to 7.8m pounds in the full year 2012 from 7.7m pounds one year earlier.
In its preliminary results for the year ending December 31st, the company stated that fundraising of £11.6m was completed in July 2012 with net proceeds £10.1m.
Operational highlights included the Sanofi ocular partnership nearing successful conclusion with $53m committed to date.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The company also reported that the ProSavin Phase I/II study successfully met primary endpoints while industry collaborations validated Oxford BioMedica's 5T4 tumour antigen technology.
John Dawson, Chief Executive Officer of Oxford BioMedica, said: "During 2012 we reported positive developments across our core clinical programmes, strengthened our LentiVector technology platform and secured MHRA[UK Medicines and Healthcare products Regulatory Agency] approval for our GMP[good manufacturing practice] manufacturing plant.
"Macroeconomic conditions remain challenging, however sentiment towards the biopharmaceutical sector is improving and we are seeing more interest than ever in personalised medicines and niche disease indications, all of which positions Oxford BioMedica well for further developments in the year ahead."
Oxford BioMedica's share price was up 1.69% to 2.40% to 2.40p at 10:41 on Wednesday.
MF
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.
-
Inflation holds steady at 3.8% ahead of BoE meeting
The rate of inflation did not rise in August, but the Bank of England is still expected to keep interest rates on hold tomorrow
-
Thousands of savers with £250k pensions take cash over tax-free money and IHT fears
With a record £70 billion withdrawn from pensions in the year to March, experts are concerned savers are making knee-jerk decisions without advice that could affect their long term wealth